Publications

Averdunk, L.; Huetzen, M. A.; Moreno-Andrés, D.; Kalb, R.; McKee, S.; Hsieh, T.-C.; Seibt, A.; Schouwink, M.; Lalani, S.; Faqeih, E. A. et al.; Brunet, T.; Boor, P.; Neveling, K.; Hoischen, A.; Hildebrandt, B.; Graf, E.; Lu, L.; Jin, W.; Schaper, J.; Omer, J. A.; Demaret, T.; Fleischer, N.; Schindler, D.; Krawitz, P.; Mayatepek, E.; Wieczorek, D.; Wang, L. L.; Antonin, W.; Jachimowicz, R. D.; von Felbert, V.; Distelmaier, F.: Biallelic variants in CRIPT cause a Rothmund-Thomson-like syndrome with increased cellular senescence. Genetics in Medicine, 100836, p. 100836 (2023)

Flümann, R.; Hansen, J.; Pelzer, B. W.; Nieper, P.; Lohmann, T.; Kisis, I.; Riet, T.; Kohlhas, V.; Nguyen, P. H.; Peifer, M. et al.; Abedpour, N.; Bosco, G.; Thomas, R. K.; Kochanek, M.; Knufer, J.; Jonigkeit, L.; Beleggia, F.; Holzem, A.; Buttner, R.; Lohneis, P.; Meinel, J.; Ortmann, M.; Persigehl, T.; Hallek, M.; Calado, D. P.; Chmielewski, M.; Klein, S.; Gothert, J. R.; Chapuy, B.; Zevnik, B.; Wunderlich, F. T.; von Tresckow, B.; Jachimowicz, R. D.; Melnick, A. M.; Reinhardt, H. C.; Knittel, G.: Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies. Blood Cancer Discov (2022)

Kobayashi, Y.; Bustos, M. A.; Shoji, Y.; Jachimowicz, R. D.; Shiloh, Y.; Hoon, D. S. B.: Genomic Amplification of UBQLN4 Is a Prognostic and Treatment Resistance Factor. Cells 11 (20) (2022)

Ratz, L.; Brambillasca, C.; Bartke, L.; Huetzen, M. A.; Goergens, J.; Leidecker, O.; Jachimowicz, R. D.; van de Ven, M.; Proost, N.; Siteur, B. et al.; de Korte-Grimmerink, R.; Bouwman, P.; Pulver, E. M.; de Bruijn, R.; Isensee, J.; Hucho, T.; Pandey, G.; van Lohuizen, M.; Mallmann, P.; Reinhardt, H. C.; Jonkers, J.; Puppe, J.: Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer. Breast Cancer Res 24 (1), p. 41 (2022)

Sprute, R.; Hieber, M. L.; Jachimowicz, R. D.: Correspondence to: hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection (2022)

Hieber, M. L.; Sprute, R.; Eichenauer, D. A.; Hallek, M.; Jachimowicz, R. D.: Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection, pp. 1 - 6 (2022)

Jachimowicz, R. D.; Klapper, W.; Glehr, G.; Muller, H.; Haverkamp, H.; Thorns, C.; Hansmann, M. L.; Moller, P.; Stein, H.; Rehberg, T. et al.; von Tresckow, B.; Reinhardt, H. C.; Borchmann, P.; Chan, F. C.; Spang, R.; Scott, D. W.; Engert, A.; Steidl, C.; Altenbuchinger, M.; Rosenwald, A.: Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. Leukemia 35 (12), pp. 3589 - 3593 (2021)

Murakami, T.; Shoji, Y.; Nishi, T.; Chang, S. C.; Jachimowicz, R. D.; Hoshimoto, S.; Ono, S.; Shiloh, Y.; Takeuchi, H.; Kitagawa, Y. et al.; Hoon, D. S. B.; Bustos, M. A.: Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. Mol Oncol 15 (4), pp. 1069 - 1087 (2021)

Schmidt, J.; Goergens, J.; Pochechueva, T.; Kotter, A.; Schwenzer, N.; Sitte, M.; Werner, G.; Altmüller, J.; Thiele, H.; Nürnberg, P. et al.; Isensee, J.; Li, Y.; Müller, C.; Leube, B.; Reinhardt, H. C.; Hucho, T.; Salinas, G.; Helm, M.; Jachimowicz, R. D.; Wieczorek, D.; Kohl, T.; Lehnart, S. E.; Yigit, G.; Wollnik, B.: Biallelic variants in YRDC cause a developmental disorder with progeroid features. Human Genetics 12 (140), pp. 1679 - 1693 (2021)

Bröckelmann, P. J.; de Jong, M. R. W.; Jachimowicz, R. D.: Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma. Cells 9 (10), p. 2287 (2020)

Jachimowicz, R. D.; Pieper, L.; Reinke, S.; Gontarewicz, A.; Plutschow, A.; Haverkamp, H.; Frauenfeld, L.; Fend, F.; Overkamp, M.; Jochims, F. et al.; Thorns, C.; Hansmann, M. L.; Moller, P.; Rosenwald, A.; Stein, H.; Reinhardt, H. C.; Borchmann, P.; von Tresckow, B.; Engert, A.; Klapper, W.: Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica 106 (6), pp. 1684 - 1692 (2020)

Riabinska, A.; Lehrmann, D.; Jachimowicz, R. D.; Knittel, G.; Fritz, C.; Schmitt, A.; Geyer, A.; Heneweer, C.; Wittersheim, M.; Frenzel, L. P. et al.; Torgovnick, A.; Wiederstein, J. L.; Wunderlich, C. M.; Ortmann, M.; Paillard, A.; Wossmann, W.; Borkhardt, A.; Burdach, S.; Hansmann, M. L.; Rosenwald, A.; Perner, S.; Mall, G.; Klapper, W.; Merseburg, A.; Kruger, M.; Grull, H.; Persigehl, T.; Wunderlich, F. T.; Peifer, M.; Utermohlen, O.; Buttner, R.; Beleggia, F.; Reinhardt, H. C.: ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. Leukemia 34 (3), pp. 771 - 786 (2019)

Dammert, M. A.; Bragelmann, J.; Olsen, R. R.; Bohm, S.; Monhasery, N.; Whitney, C. P.; Chalishazar, M. D.; Tumbrink, H. L.; Guthrie, M. R.; Klein, S. et al.; Ireland, A. S.; Ryan, J.; Schmitt, A.; Marx, A.; Ozretic, L.; Castiglione, R.; Lorenz, C.; Jachimowicz, R. D.; Wolf, E.; Thomas, R. K.; Poirier, J. T.; Buttner, R.; Sen, T.; Byers, L. A.; Reinhardt, H. C.; Letai, A.; Oliver, T. G.; Sos, M. L.: MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun 10 (1), p. 3485 (2019)

Jachimowicz, R. D.; Reinhardt, H. C.: UBQLN4 promotes non-homologous end joining by repressing DNA end-resection. Mol Cell Oncol 6 (2), p. 1575692 (2019)

Jachimowicz, R. D.; Goergens, J.; Reinhardt, H. C.: DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. Cell Cycle 18 (13), pp. 1423 - 1434 (2019)

Jachimowicz, R. D.; Beleggia, F.; Isensee, J.; Velpula, B. B.; Goergens, J.; Bustos, M. A.; Doll, M. A.; Shenoy, A.; Checa-Rodriguez, C.; Wiederstein, J. L. et al.; Baranes-Bachar, K.; Bartenhagen, C.; Hertwig, F.; Teper, N.; Nishi, T.; Schmitt, A.; Distelmaier, F.; Ludecke, H. J.; Albrecht, B.; Kruger, M.; Schumacher, B.; Geiger, T.; Hoon, D. S. B.; Huertas, P.; Fischer, M.; Hucho, T.; Peifer, M.; Ziv, Y.; Reinhardt, H. C.; Wieczorek, D.; Shiloh, Y.: UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell 176 (3), pp. 505 - 519 e22 (2019)

Herling, C. D.; Abedpour, N.; Weiss, J.; Schmitt, A.; Jachimowicz, R. D.; Merkel, O.; Cartolano, M.; Oberbeck, S.; Mayer, P.; Berg, V. et al.; Thomalla, D.; Kutsch, N.; Stiefelhagen, M.; Cramer, P.; Wendtner, C. M.; Persigehl, T.; Saleh, A.; Altmuller, J.; Nurnberg, P.; Pallasch, C.; Achter, V.; Lang, U.; Eichhorst, B.; Castiglione, R.; Schafer, S. C.; Buttner, R.; Kreuzer, K. A.; Reinhardt, H. C.; Hallek, M.; Frenzel, L. P.; Peifer, M.: Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun 9 (1), p. 727 (2018)

Jachimowicz, R. D.; Engert, A.: The challenging aspects of managing adolescents and young adults with Hodgkin's lymphoma. Acta Haematol 132 (3-4), pp. 274 - 8 (2014)

Jachimowicz, R. D.; Borchmann, S.; Rothe, A.: Multi-specific antibodies for cancer immunotherapy. BioDrugs 28 (4), pp. 331 - 43 (2014)

Dietlein, F.; Thelen, L.; Jokic, M.; Jachimowicz, R. D.; Ivan, L.; Knittel, G.; Leeser, U.; van Oers, J.; Edelmann, W.; Heukamp, L. C. et al.; Reinhardt, H. C.: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov 4 (5), pp. 592 - 605 (2014)